Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shay Fish

Podiatrist, Foot & Ankle Surgery Kerrville, TX Doctor of Podiatric Medicine

NPI 1134217516 CMS profile 5662

420 Water St, Suite 107, Kerrville, TX 78028

Open in the dashboard

General payments

$24,012

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shay Fish of Kerrville, TX is reported in the CMS Open Payments database as having received $24,012 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $992 16
2024 General $15,773 22
2023 General $2,759 15
2022 General $2,592 20
2021 General $1,278 5
2020 General $206 4
2019 General $411 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shay Fish
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Shay Fish were reported at $992. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Shay Fish Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $411 $389 $118–$1,406 $163
2020 $206 $191 $62–$691 $114
2021 $1,278 $329 $104–$1,341 $132
2022 $2,592 $419 $125–$1,611 $149
2023 $2,759 $377 $128–$1,164 $160
2024 $15,773 $394 $134–$1,168 $164
2025 $992 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $14,000 2 payments
  2. Treace Medical Concepts, Inc. $5,202 35 payments
  3. Stryker Corporation $1,546 20 payments
  4. Medinc of Texas $1,200 1 payment
  5. Mission Medical Distribution, LLC $794 5 payments
  6. Arthrex, Inc. $689 8 payments
  7. Smith+Nephew, Inc. $225 7 payments
  8. MedShape, Inc. $90 1 payment
  9. Sebela Pharmaceuticals Inc. $71 3 payments
  10. DePuy Synthes Sales Inc. $45 2 payments
  11. Other $149 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $14,000 2 payments
  2. Food and Beverage $4,470 78 payments
  3. Travel and Lodging $4,342 10 payments
  4. Education $1,201 2 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $14,018 3 payments
  2. LAPIPLASTY SYSTEM $4,023 29 payments
  3. Lapiplasty $938 1 payment
  4. AUGMENT INJECTABLE $351 4 payments
  5. AXSOS $288 2 payments
  6. ALLOGRAFT $194 2 payments
  7. LAPIPLASTY SYSTEM 1 $175 3 payments
  8. VARIAX $168 1 payment
  9. EASY CLIP $167 2 payments
  10. PROSTEP MICA $160 1 payment
  11. Other $1,822 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

322

Median for Podiatry: 160

Drug cost

$2,279

Median for Podiatry: $2,368

Branded share of claims

13%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 29 $689
Cephalexin Generic 67 $343
Itraconazole Generic 16 $241
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $180
Gabapentin Generic 27 $131
Naproxen Generic 27 $118
Celecoxib Generic 12 $107
Ciprofloxacin Hcl Generic 16 $107
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $105
Clindamycin Hcl Generic 13 $63

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 137 billing codes

Paid by Medicare

$256,621

Of which drugs: $116

Medicare patients

677

Average age 76

Services billed

4,789

413 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 35%
Ischemic heart disease 31%
Chronic kidney disease 26%
Depression 21%
Atrial fibrillation 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 88 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record